RxDoctor Payments Data

Blanca Mora

Physician Assistant · Alhambra, CANPI 1154490118

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.3% of the total across 250 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Amgen at 40.1% of the total. Reporting peaked in 2024 at $2,692 and has fallen 81.6% since, to $495 in 2025. Among physician assistant clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,826in general payments, 2019–2025

Across 250 payments — averaging $19.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • AbbVie$701
  • GSK$417
  • Novartis$378
  • Aurinia Pharma U.S., Inc.$200
  • Johnson & Johnson$181
  • plus $1K from 17 others

What the payments were for

  • Consulting fees$1754%
  • Food & beverage$4,55194%
  • Education$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,826 in reported general payments places this provider in the 90th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California →

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept88$664,001
Humira(Cf) PenAdalimumab63$463,856
Orencia ClickjectAbatacept26$151,133
RinvoqUpadacitinib15$120,774
OtezlaApremilast19$87,674
Cimzia (2 Pack)Certolizumab Pegol16$86,808
ProliaDenosumab44$75,323
Actemra ActpenTocilizumab14$67,133
SimponiGolimumab11$65,814
RasuvoMethotrexate/Pf72$42,177
Teriparatide22$42,023
Evenity (2 Syringes)Romosozumab-Aqqg12$29,080
Diclofenac Sodium125$17,385
Mycophenolate Mofetil20$14,264
Hydroxychloroquine Sulfate193$5,895

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla, Prolia, Evenity (2 Syringes)$1,937$192,07775 claims
AbbVieRinvoq$701$120,77415 claims
UCB, Inc.Cimzia (2 Pack)$113$86,80816 claims
Johnson & JohnsonSimponi$181$65,81411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Alhambra

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →